Crescent Biopharma, Inc.
corporate_fare Company Profile
Crescent Biopharma, Inc. (NASDAQ:CBIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for CBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for CBIO spans 10-Q, 8-K, SCHEDULE 13D/A, 424B5.
Recent high-impact activity:
- Crescent Biopharma Posts $289.4M Cash, Runway Into H2 2028 as Q3 Loss Widens
- Crescent Biopharma Q3: $289.4M Cash, $37.7M Quarterly Loss, CR-002 Trial Underway
- Crescent Biopharma Lays Out CR-001/CR-002/CR-003 Data Calendar; APOLLO Starts Q4 2026
- FDA Clears IND for Crescent's PD-L1 ADC CR-002, Phase 1/2 APOLLO Trial to Start Q4
- Crescent Biopharma Q2 Loss Narrows to $24.8M; Pro Forma Cash Hits $305M, Runway Into 2028
Financial Snapshot
Short Interest & Short Volume
16.29 days to coverFINRA reported short interest of 4,160,829 shares in CBIO as of the October 30, 2026 settlement, a 5.8% decrease from the prior period — about 16.3 days to cover at its recent average daily volume. On November 20, 2026, 59.9% of CBIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for CBIO, detected from its recent SEC filings · based on capital-structure filings through 2026-07-15.
Offering Priced at $14.50/Share · Net Proceeds of ~$115.9 Million
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →